MarketPulse

cutaneous T-cell lymphoma

4 articles
BenzingaBenzinga··Soligenix, Inc.

Soligenix's HyBryte Shows Promise Against Cutaneous Lymphoma at 2026 Workshop

Soligenix's HyBryte™ cutaneous lymphoma therapy shows positive results ahead of 2026 presentation, with FDA awarding $2.6M development grant.
SNGXPhase 3 clinical trialFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Ibn

Soligenix Reports Promising 48% Response Rate in HyBryte Phase 3 Study

Soligenix's HyBryte study shows 48% response rate, nearly double the 25% threshold, with interim results expected this quarter.
SNGXPhase 3 clinical trialbiotech
BenzingaBenzinga··Prnewswire

Citius Pharma Posts Inaugural Revenue on LYMPHIR™ Commercial Launch

Citius Pharma reports first revenue of $3.9M from LYMPHIR™ launch, raises $20.9M to support growth and advance pipeline candidates.
CTXRCTORorphan drugimmunotherapy
BenzingaBenzinga··Prnewswire

Citius Oncology Posts Maiden Revenue of $3.9M From LYMPHIR Launch

Citius Oncology reports maiden revenue of $3.9M from LYMPHIR immunotherapy launch in December 2025, marking transition to commercial-stage biopharmaceutical company.
CTXRCTORnet lossFDA approval